PNPLA3 and type 2 diabetes mellitus: Our study has some limitations that should be noticed and restrict the extrapolation of our results to the general population, such as: (a) the sample size may have limited the interpretation of the role that T2D and PNPLA3 p.I148M and TM6SF2 p.E167K polymorphisms play in the development of advanced fibrosis; (b) T2D patients were predominant in the NASH cohort and may have disturbed the results regarding the effect of both polymorphisms in advanced fibrosis in the absence of diabetes.